{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:48:40Z","timestamp":1787726920365,"version":"build-2784847793"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000765","name":"University College London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000765","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012317","name":"UCLH Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012317","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.lungcan.2024.107921","type":"journal-article","created":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T19:39:18Z","timestamp":1722973158000},"page":"107921","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation"],"prefix":"10.1016","volume":"196","author":[{"given":"David M.","family":"Waterhouse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1304-9340","authenticated-orcid":false,"given":"Sacha","family":"Rothschild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7324-7977","authenticated-orcid":false,"given":"Christophe","family":"Dooms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Mennecier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farastuk","family":"Bozorgmehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Majem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel H.","family":"van den Heuvel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Linardou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byoung","family":"Chul Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Roberts-Thomson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2698-4362","authenticated-orcid":false,"given":"Normand","family":"Blais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Schvartsman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Holmskov Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0948-9071","authenticated-orcid":false,"given":"Izabela","family":"Chmielewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin D.","family":"Forster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Giannopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3189-409X","authenticated-orcid":false,"given":"Bj\u00f6rn","family":"Stollenwerk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia C.","family":"Obiozor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7653-9748","authenticated-orcid":false,"given":"Silvia","family":"Novello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2024.107921_b0005","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1200\/JCO.21.01626","article-title":"Targeted therapies for lung cancer patients with oncogenic driver molecular alterations","volume":"40","author":"Tan","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2024.107921_b0010","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11864-019-0617-6","article-title":"The role of angiogenesis inhibitors in the era of immune checkpoint inhibitors and targeted therapy in metastatic non-small cell lung cancer","volume":"20","author":"Perdrizet","year":"2019","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.lungcan.2024.107921_b0015","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1200\/JCO.21.01497","article-title":"First-line immunotherapy for non-small-cell lung cancer","volume":"40","author":"Reck","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2024.107921_b0020","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41568-019-0179-8","article-title":"Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy","volume":"19","author":"Skoulidis","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.lungcan.2024.107921_b0025","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1158\/2159-8290.CD-16-1337","article-title":"Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies","volume":"7","author":"Jordan","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.lungcan.2024.107921_b0030","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.cancergen.2016.03.001","article-title":"The potential utility of re-mining results of somatic mutation testing: KRAS status in lung adenocarcinoma","volume":"209","author":"Biernacka","year":"2016","journal-title":"Cancer Genet"},{"key":"10.1016\/j.lungcan.2024.107921_b0035","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1038\/s41388-018-0634-0","article-title":"Impact of RAS mutation subtype on clinical outcome\u2014a cross-entity comparison of patients with advanced non-small cell lung cancer and colorectal cancer","volume":"38","author":"Wiesweg","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.lungcan.2024.107921_b0040","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1158\/1078-0432.CCR-17-1841","article-title":"Effects of co-occurring genomic alterations on outcomes in patients with KRAS-mutant non-small cell lung cancer","volume":"24","author":"Arbour","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.lungcan.2024.107921_b0045","first-page":"156","article-title":"Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer","volume":"4","author":"Kohno","year":"2015","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.lungcan.2024.107921_b0050","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1186\/s12885-022-10246-7","article-title":"Differential properties of KRAS transversion and transition mutations in non-small cell lung cancer: associations with environmental factors and clinical outcomes","volume":"22","author":"Sato","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.lungcan.2024.107921_b0055","article-title":"Prognostic characteristics and immunotherapy response of patients with nonsquamous NSCLC with KRAS mutation in East Asian populations: a single-center cohort study in Taiwan","volume":"2","author":"Wu","year":"2020","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.lungcan.2024.107921_b0060","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1093\/annonc\/mdt205","article-title":"Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology","volume":"24","author":"Dearden","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lungcan.2024.107921_b0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2021.05.026","article-title":"A retrospective observational study of the natural history of advanced non-small-cell lung cancer in patients with KRAS p.G12C mutated or wild-type disease","volume":"159","author":"Spira","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2024.107921_b0070","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jtho.2018.12.013","article-title":"K-ras mutation subtypes in NSCLC and associated co-occuring mutations in other oncogenic pathways","volume":"14","author":"Scheffler","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2024.107921_b0075","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1158\/1078-0432.CCR-13-0318","article-title":"ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer","volume":"19","author":"Gainor","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.lungcan.2024.107921_b0080","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.lungcan.2024.107921_b0085","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1158\/1078-0432.CCR-21-3074","article-title":"FDA approval summary: sotorasib for KRAS G12C-mutated metastatic NSCLC","volume":"28","author":"Nakajima","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.lungcan.2024.107921_b0090","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","article-title":"for the CodeBreaK 200 Investigators, Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS(G12C) mutation: a randomised, open-label, phase 3 trial","volume":"401","author":"de Langen","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2024.107921_b0095","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1046\/j.1365-2141.1996.352889.x","article-title":"Measurement of health-related quality of life in multiple myeloma","volume":"92","author":"Wisl\u00f8ff","year":"1996","journal-title":"Nordic Myeloma Study Group, Br J Haematol"},{"key":"10.1016\/j.lungcan.2024.107921_b0100","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.lungcan.2024.107921_b0105","doi-asserted-by":"crossref","first-page":"5368","DOI":"10.1182\/blood.V122.21.5368.5368","article-title":"Continued treatment duration, drug dosing and Health-Related Quality Of Life (HRQoL) of patients with relapsed\/refractory multiple myeloma (RRMM) receiving 2nd and 3rd Line treatments: results from a European multicentre study","volume":"122","author":"Petrucci","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.lungcan.2024.107921_b0110","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/0959-8049(94)90535-5","article-title":"The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life","volume":"30a","author":"Bergman","year":"1994","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.lungcan.2024.107921_b0115","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQOL - a new facility for the measurement of health-related quality of life","volume":"16","author":"EuroQOL Group","year":"1990","journal-title":"Health Policy"},{"key":"10.1016\/j.lungcan.2024.107921_b0120","unstructured":"EuroQOL. EQ-5D-5L. Available at: https:\/\/euroqol.org\/eq-5d-instruments\/eq-5d-5l-about\/ (accessed 14 May 2024)."},{"key":"10.1016\/j.lungcan.2024.107921_b0125","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1002\/cncr.31133","article-title":"Validity and usefulness of a single-item measure of patient-reported bother from side effects of cancer therapy","volume":"124","author":"Pearman","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2024.107921_b0130","doi-asserted-by":"crossref","first-page":"dju244","DOI":"10.1093\/jnci\/dju244","article-title":"Development of the National Cancer Institute's patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)","volume":"106","author":"Basch","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.lungcan.2024.107921_b0135","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1093\/pm\/pnaa269","article-title":"Brief Pain Inventory-Short Form: a new method for assessing pain in the emergency department","volume":"21","author":"Im","year":"2020","journal-title":"Pain Med"},{"key":"10.1016\/j.lungcan.2024.107921_b0140","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1007\/s11136-022-03180-5","article-title":"PRO Consortium\u2019s Communication Subcommittee, Comparing patient global impression of severity and patient global impression of change to evaluate test-retest reliability of depression, non-small cell lung cancer, and asthma measures","volume":"31","author":"Eremenco","year":"2022","journal-title":"Qual Life Res"},{"key":"10.1016\/j.lungcan.2024.107921_b0145","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/sim.4780131106","article-title":"Analysis of repeated categorical data using generalized estimating equations","volume":"13","author":"Lipsitz","year":"1994","journal-title":"Stat Med"},{"key":"10.1016\/j.lungcan.2024.107921_b0150","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00520-013-1959-4","article-title":"The symptom burden of non-small cell lung cancer in the USA: a real-world cross-sectional study","volume":"22","author":"Iyer","year":"2014","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.lungcan.2024.107921_b0155","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jtho.2017.10.029","article-title":"Impact of nivolumab versus docetaxel on health-related quality of life and symptoms in patients with advanced squamous non-small cell lung cancer: Results from the CheckMate 017 Study","volume":"13","author":"Reck","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2024.107921_b0160","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S1470-2045(19)30801-0","volume":"21","author":"Garassino","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.lungcan.2024.107921_b0165","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1200\/JCO.19.01348","article-title":"Health-related quality of life with carboplatin-paclitaxel or nab-paclitaxel with or without pembrolizumab in patients with metastatic squamous non-small-cell lung cancer","volume":"38","author":"Mazieres","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2024.107921_b0170","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1191\/0269216305pm1001oa","article-title":"Symptom distress as rated by advanced cancer patients, caregivers and physicians in the last week of life","volume":"19","author":"Oi-Ling","year":"2005","journal-title":"Palliat Med"},{"key":"10.1016\/j.lungcan.2024.107921_b0175","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jpainsymman.2011.09.017","article-title":"Concordance between patient reports of cancer-related symptoms and medical records documentation","volume":"44","author":"Sikorskii","year":"2012","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.lungcan.2024.107921_b0180","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1093\/jnci\/djr485","article-title":"Patient self-reports of symptoms and clinician ratings as predictors of overall cancer survival","volume":"103","author":"Quinten","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.lungcan.2024.107921_b0185","doi-asserted-by":"crossref","first-page":"pkad002","DOI":"10.1093\/jncics\/pkad002","article-title":"Assessing the impact of open-label designs in patient-reported outcomes: investigation in oncology clinical trials","volume":"7","author":"Lord-Bessen","year":"2023","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.lungcan.2024.107921_b0190","doi-asserted-by":"crossref","first-page":"7363","DOI":"10.1002\/cam4.3335","article-title":"Investigating the impact of open label design on patient-reported outcome results in prostate cancer randomized controlled trials","volume":"9","author":"Mouillet","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.lungcan.2024.107921_b0195","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s11136-021-02945-8","article-title":"Impact of open-label versus blinded study design on patient-reported outcomes data in randomized clinical trials of immunotherapy in advanced or metastatic cancer patients: a systematic review","volume":"31","author":"Anota","year":"2022","journal-title":"Qual Life Res"},{"key":"10.1016\/j.lungcan.2024.107921_b0200","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jtho.2019.01.016","article-title":"Health-related quality of life in KEYNOTE-010: a phase II\/III study of pembrolizumab versus docetaxel in patients with previously treated advanced, programmed death ligand 1-expressing NSCLC","volume":"14","author":"Barlesi","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2024.107921_b0205","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1002\/ijc.33133","article-title":"Patient-reported outcomes as a prognostic marker of survival in patients with advanced nonsmall cell lung cancer treated with immunotherapy","volume":"147","author":"Hopkins","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.lungcan.2024.107921_b0210","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ejca.2014.11.015","article-title":"LUME-Lung 1 Study Group, Analysis of patient-reported outcomes from the LUME-Lung 1 trial: a randomised, double-blind, placebo-controlled, phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer","volume":"51","author":"Novello","year":"2015","journal-title":"Eur J Cancer"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500224004550?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500224004550?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T08:37:03Z","timestamp":1728463023000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500224004550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":42,"alternative-id":["S0169500224004550"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2024.107921","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2024.107921","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107921"}}